301509 金凯生科
已收盘 08-21 15:00:00
资讯
新帖
简况
破发股金凯生科跌5.72% 2023上市超募3.1亿中信建投保荐
中金财经 · 08-21 16:54
破发股金凯生科跌5.72% 2023上市超募3.1亿中信建投保荐
股市必读:金凯生科新发布《第二届董事会第十四次会议决议公告》
证券之星 · 08-21 02:21
股市必读:金凯生科新发布《第二届董事会第十四次会议决议公告》
金凯生科(301509)8月10日股东户数1.57万户,较上期增加12.92%
证券之星 · 08-20 17:39
金凯生科(301509)8月10日股东户数1.57万户,较上期增加12.92%
金凯生科(301509.SZ)发布上半年业绩,归母净利润3027.25万元,同比下降57.81%
智通财经 · 08-20 17:37
金凯生科(301509.SZ)发布上半年业绩,归母净利润3027.25万元,同比下降57.81%
金凯生科:公司目前业务不涉及CAR-T细胞疗法相关领域
证券之星 · 08-18
金凯生科:公司目前业务不涉及CAR-T细胞疗法相关领域
破发股金凯生科跌3.11% 2023上市超募3.1亿中信建投保荐
中金财经 · 08-17
破发股金凯生科跌3.11% 2023上市超募3.1亿中信建投保荐
股市必读:金凯生科(301509)股东户数1.57万户,较上期增加12.92%
证券之星 · 08-12
股市必读:金凯生科(301509)股东户数1.57万户,较上期增加12.92%
金凯生科:截至2026年8月10日,公司股东数为15,666户
证券之星 · 08-11
金凯生科:截至2026年8月10日,公司股东数为15,666户
金凯生科(301509)7月31日股东户数1.39万户,较上期减少0.45%
证券之星 · 08-04
金凯生科(301509)7月31日股东户数1.39万户,较上期减少0.45%
金凯生科:截至2026年7月31日,公司股东数为13,874户
证券之星 · 08-04
金凯生科:截至2026年7月31日,公司股东数为13,874户
金凯生科(301509)披露向2026年限制性股票与股票增值权激励计划激励对象首次授予限制性股票及股票增值权的公告,7月27日股价上涨3.44%
证券之星 · 07-27
金凯生科(301509)披露向2026年限制性股票与股票增值权激励计划激励对象首次授予限制性股票及股票增值权的公告,7月27日股价上涨3.44%
股市必读:金凯生科(301509)股东户数1.39万户,较上期减少0.21%
证券之星 · 07-23
股市必读:金凯生科(301509)股东户数1.39万户,较上期减少0.21%
金凯生科(301509)披露2026年限制性股票与股票增值权激励计划首次授予激励对象名单核查及公示情况,7月21日股价下跌6.81%
证券之星 · 07-21
金凯生科(301509)披露2026年限制性股票与股票增值权激励计划首次授予激励对象名单核查及公示情况,7月21日股价下跌6.81%
7月21日金凯生科跌6.81%,富安达健康人生混合A基金重仓该股
证券之星 · 07-21
7月21日金凯生科跌6.81%,富安达健康人生混合A基金重仓该股
7月17日金凯生科跌8.33%,富安达健康人生混合A基金重仓该股
证券之星 · 07-17
7月17日金凯生科跌8.33%,富安达健康人生混合A基金重仓该股
7月15日金凯生科涨7.17%,富安达健康人生混合A基金重仓该股
证券之星 · 07-15
7月15日金凯生科涨7.17%,富安达健康人生混合A基金重仓该股
股市必读:金凯生科(301509)股东户数1.4万户,较上期增加0.6%
证券之星 · 07-14
股市必读:金凯生科(301509)股东户数1.4万户,较上期增加0.6%
7月13日金凯生科跌5.09%,富安达健康人生混合A基金重仓该股
证券之星 · 07-13
7月13日金凯生科跌5.09%,富安达健康人生混合A基金重仓该股
金凯生科(301509)发布2026年限制性股票与股票增值权激励计划(草案),7月10日股价上涨2.51%
证券之星 · 07-10
金凯生科(301509)发布2026年限制性股票与股票增值权激励计划(草案),7月10日股价上涨2.51%
金凯生科(301509)6月30日股东户数1.39万户,较上期增加5.19%
证券之星 · 07-07
金凯生科(301509)6月30日股东户数1.39万户,较上期增加5.19%
加载更多
公司概况
公司名称:
金凯(辽宁)生命科技股份有限公司
所属行业:
医药制造业
上市日期:
2023-08-03
主营业务:
金凯(辽宁)生命科技股份有限公司的主营业务是提供小分子药物中间体以及少量原料药的定制研发生产服务。公司的主要产品是中间体。
发行价格:
56.56
{"stockData":{"symbol":"301509","market":"SZ","secType":"STK","nameCN":"金凯生科","latestPrice":30.82,"timestamp":1787295828000,"preClose":32.69,"halted":0,"volume":6206948,"delay":0,"changeRate":-0.0572,"floatShares":56740900,"shares":120000000,"eps":0.5258,"marketStatus":"已收盘","change":-1.87,"latestTime":"08-21 15:00:00","open":31.28,"high":31.48,"low":30.16,"amount":191000000,"amplitude":0.0404,"askPrice":30.83,"askSize":40,"bidPrice":30.82,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.5258,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":5,"adr":0,"adjPreClose":32.69,"symbolType":"stock","openAndCloseTimeList":[[1787275800000,1787283000000],[1787288400000,1787295600000]],"highLimit":35.96,"lowLimit":29.42,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":120446669,"isCdr":false,"pbRate":1.77,"roa":"--","peRate":58.615443,"roe":"1.37%","epsLYR":0.87,"committee":-0.140097,"marketValue":3712000000,"turnoverRate":0.1094,"status":1,"floatMarketCap":1749000000},"requestUrl":"/m/hq/s/301509/","defaultTab":"news","newsList":[{"id":"2661626507","title":"破发股金凯生科跌5.72% 2023上市超募3.1亿中信建投保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2661626507","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661626507?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:54","pubTimestamp":1787302446,"startTime":"0","endTime":"0","summary":"中国经济网北京8月21日讯 金凯生科 今日收报30.82元,跌幅5.72%。目前该股处于破发状态。 金凯生科于2023年8月3日在深交所创业板上市,发行股份数量为2,150.8335万股,发行股份占本次发行后公司股份总数的比例为25.00%,发行价格为56.56元/股。金凯生科本次发行的保荐机构为中信建投证券股份有限公司,保荐代表人为逯金才、张林。 金凯生科本次公开发行新股的发行费用合计10,576.71万元,其中中信建投证券股份有限公司获得保荐及承销费用8,654.56万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260821/32342832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0276","601066","BK0239","IPOS","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661023136","title":"股市必读:金凯生科新发布《第二届董事会第十四次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2661023136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661023136?lang=zh_cn&edition=full","pubTime":"2026-08-21 02:21","pubTimestamp":1787250070,"startTime":"0","endTime":"0","summary":"公司公告汇总第二届董事会第十四次会议决议公告2026年8月20日召开第二届董事会第十四次会议,审议通过《2026年半年度报告》及其摘要、《2026年半年度募集资金存放、管理与使用情况的专项报告》、使用部分闲置募集资金及自有资金进行现金管理、使用部分超募资金永久补充流动资金,以及提请召开2026年第二次临时股东会等议案,全部获全票通过;会议由董事长FUMIN WANG主持,审计委员会已审议通过相关议案,部分事项尚需提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100001860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660288385","title":"金凯生科(301509)8月10日股东户数1.57万户,较上期增加12.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660288385","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660288385?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:39","pubTimestamp":1787218786,"startTime":"0","endTime":"0","summary":"证券之星消息,近日金凯生科披露,截至2026年8月10日公司股东户数为1.57万户,较7月31日增加1792.0户,增幅为12.92%。在医疗服务行业个股中,金凯生科股东户数低于行业平均水平,截至8月10日,医疗服务行业平均股东户数为4.78万户。从股价来看,2026年7月31日至2026年8月10日,金凯生科区间涨幅为18.53%,在此期间股东户数增加1792.0户,增幅为12.92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000031923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660003400","title":"金凯生科(301509.SZ)发布上半年业绩,归母净利润3027.25万元,同比下降57.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660003400","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660003400?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:37","pubTimestamp":1787218629,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金凯生科(301509.SZ)发布2026年半年度报告,报告期内,公司实现营业收入3.09亿元,同比下降11.22%。实现归属于上市公司股东的净利润3027.25万元,同比下降57.81%。实现归属于上市公司股东的扣除非经常性损益的净利润2302.51万元,同比下降61.09%。基本每股收益0.25元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660450291","title":"金凯生科:公司目前业务不涉及CAR-T细胞疗法相关领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2660450291","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660450291?lang=zh_cn&edition=full","pubTime":"2026-08-18 15:54","pubTimestamp":1787039649,"startTime":"0","endTime":"0","summary":"证券之星消息,金凯生科(301509)08月18日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司是否有涉及CAR-T细胞疗法方面的项目?金凯生科回复:尊敬的投资者,您好!公司目前业务不涉及CAR-T细胞疗法相关领域。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800024358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660148385","title":"破发股金凯生科跌3.11% 2023上市超募3.1亿中信建投保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2660148385","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660148385?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:14","pubTimestamp":1786954451,"startTime":"0","endTime":"0","summary":"中国经济网北京8月17日讯 金凯生科 今日收报32.75元,跌幅3.11%。目前该股处于破发状态。 金凯生科于2023年8月3日在深交所创业板上市,发行股份数量为2,150.8335万股,发行股份占本次发行后公司股份总数的比例为25.00%,发行价格为56.56元/股。金凯生科本次发行的保荐机构为中信建投证券股份有限公司,保荐代表人为逯金才、张林。 金凯生科本次公开发行新股的发行费用合计10,576.71万元,其中中信建投证券股份有限公司获得保荐及承销费用8,654.56万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260817/32337054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","IPOS","BK0276","301509","601066"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658129089","title":"股市必读:金凯生科(301509)股东户数1.57万户,较上期增加12.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658129089","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658129089?lang=zh_cn&edition=full","pubTime":"2026-08-12 01:19","pubTimestamp":1786468749,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘,金凯生科报收于32.04元,上涨0.56%,换手率10.24%,成交量5.81万手,成交额1.87亿元。当日关注点交易信息汇总:8月11日主力资金净流出1116.1万元,占总成交额5.98%。股本股东变化:截至2026年8月10日,金凯生科股东户数为1.57万户,较7月31日增加12.92%。股本股东变化股东户数变动截至2026年8月10日公司股东户数为1.57万户,较7月31日增加1792.0户,增幅为12.92%;户均持股数量由上期的8681.0股减少至7688.0股,户均持股市值为24.5万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200001605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658960305","title":"金凯生科:截至2026年8月10日,公司股东数为15,666户","url":"https://stock-news.laohu8.com/highlight/detail?id=2658960305","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658960305?lang=zh_cn&edition=full","pubTime":"2026-08-11 15:18","pubTimestamp":1786432701,"startTime":"0","endTime":"0","summary":"证券之星消息,金凯生科(301509)08月11日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止2026年8月10日,公司股东人数多少?金凯生科回复:尊敬的投资者,您好!截至2026年8月10日,公司股东数为15,666户。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100018998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656312995","title":"金凯生科(301509)7月31日股东户数1.39万户,较上期减少0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656312995","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656312995?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:53","pubTimestamp":1785837237,"startTime":"0","endTime":"0","summary":"证券之星消息,近日金凯生科披露,截至2026年7月31日公司股东户数为1.39万户,较7月20日减少63.0户,减幅为0.45%。在医疗服务行业个股中,金凯生科股东户数低于行业平均水平,截至7月31日,医疗服务行业平均股东户数为4.87万户。从股价来看,2026年7月20日至2026年7月31日,金凯生科区间跌幅为10.73%,在此期间股东户数减少63.0户,减幅为0.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400030153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656583442","title":"金凯生科:截至2026年7月31日,公司股东数为13,874户","url":"https://stock-news.laohu8.com/highlight/detail?id=2656583442","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656583442?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:36","pubTimestamp":1785803770,"startTime":"0","endTime":"0","summary":"证券之星消息,金凯生科(301509)08月03日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘你好,请问截止到7月31日收盘,公司股东人数有多少?谢谢金凯生科回复:尊敬的投资者,您好!截至2026年7月31日,公司股东数为13,874户。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400007746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654049853","title":"金凯生科(301509)披露向2026年限制性股票与股票增值权激励计划激励对象首次授予限制性股票及股票增值权的公告,7月27日股价上涨3.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654049853","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654049853?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:48","pubTimestamp":1785163696,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘,金凯生科报收于27.68元,较前一交易日上涨3.44%,最新总市值为33.34亿元。金凯(辽宁)生命科技股份有限公司于近日向73名激励对象首次授予207.00万股限制性股票,授予价格为15.13元/股,占公司总股本的1.72%;同时向20名激励对象授予27.00万份股票增值权,占公司总股本的0.22%。本次授予的限制性股票与股票增值权的授予日均为2026年7月27日,激励对象包括董事、高级管理人员、中层管理人员及核心业务人员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700035257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653620857","title":"股市必读:金凯生科(301509)股东户数1.39万户,较上期减少0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653620857","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653620857?lang=zh_cn&edition=full","pubTime":"2026-07-23 01:51","pubTimestamp":1784742666,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘,金凯生科报收于28.15元,上涨0.32%,换手率6.17%,成交量3.5万手,成交额1.0亿元。当日关注点交易信息汇总:7月22日主力资金净流入317.18万元,占总成交额0.0%。股本股东变化:截至2026年7月20日,金凯生科股东户数为1.39万户,较7月10日减少30.0户,减幅0.21%。户均持股数量由上期的8624.0股增加至8642.0股,户均持股市值为26.02万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300001810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653205604","title":"金凯生科(301509)披露2026年限制性股票与股票增值权激励计划首次授予激励对象名单核查及公示情况,7月21日股价下跌6.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653205604","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653205604?lang=zh_cn&edition=full","pubTime":"2026-07-21 22:20","pubTimestamp":1784643615,"startTime":"0","endTime":"0","summary":"金凯(辽宁)生命科技股份有限公司于2026年7月21日披露《董事会薪酬与考核委员会关于2026年限制性股票与股票增值权激励计划首次授予激励对象名单的核查意见及公示情况说明》。公告显示,公司于2026年7月11日至7月20日期间通过内部公示栏对2026年限制性股票与股票增值权激励计划首次授予激励对象的姓名及职务进行公示,员工可通过书面、电话、邮件等方式反馈意见;公示期内未收到任何异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100044650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653278630","title":"7月21日金凯生科跌6.81%,富安达健康人生混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653278630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653278630?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:01","pubTimestamp":1784624466,"startTime":"0","endTime":"0","summary":"证券之星消息,7月21日金凯生科跌6.81%,收盘报28.06元,换手率8.96%,成交量5.08万手,成交额1.42亿元。重仓金凯生科的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为富安达基金的富安达健康人生混合A。富安达健康人生混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100031273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652549409","title":"7月17日金凯生科跌8.33%,富安达健康人生混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652549409","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652549409?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:03","pubTimestamp":1784279011,"startTime":"0","endTime":"0","summary":"证券之星消息,7月17日金凯生科跌8.33%,收盘报30.16元,换手率9.0%,成交量5.1万手,成交额1.58亿元。重仓金凯生科的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为富安达基金的富安达健康人生混合A。富安达健康人生混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455356","title":"7月15日金凯生科涨7.17%,富安达健康人生混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651455356?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:38","pubTimestamp":1784104706,"startTime":"0","endTime":"0","summary":"证券之星消息,7月15日金凯生科涨7.17%,收盘报32.27元,换手率11.24%,成交量6.38万手,成交额2.01亿元。重仓金凯生科的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为富安达基金的富安达健康人生混合A。富安达健康人生混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500031265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651678146","title":"股市必读:金凯生科(301509)股东户数1.4万户,较上期增加0.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651678146","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651678146?lang=zh_cn&edition=full","pubTime":"2026-07-14 02:02","pubTimestamp":1783965740,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘,金凯生科报收于29.09元,下跌5.09%,换手率5.92%,成交量3.36万手,成交额9986.97万元。当日关注点交易信息汇总:7月13日主力资金净流出313.66万元,占总成交额0.0%。股本股东变化:截至2026年7月10日,金凯生科股东户数为1.4万户,较6月30日增加83.0户,增幅0.6%。户均持股数量由上期的8675.0股减少至8624.0股,户均持股市值为26.43万元。董秘最新回复投资者: 请问截止2026年7月10日,公司股东人数多少?截至2026年7月10日,公司股东数为13,967户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400001490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651197380","title":"7月13日金凯生科跌5.09%,富安达健康人生混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651197380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651197380?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:02","pubTimestamp":1783933368,"startTime":"0","endTime":"0","summary":"证券之星消息,7月13日金凯生科跌5.09%,收盘报29.09元,换手率5.92%,成交量3.36万手,成交额9986.97万元。重仓金凯生科的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为富安达基金的富安达健康人生混合A。富安达健康人生混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300024209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650135122","title":"金凯生科(301509)发布2026年限制性股票与股票增值权激励计划(草案),7月10日股价上涨2.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650135122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650135122?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:23","pubTimestamp":1783693393,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,金凯生科报收于30.65元,较前一交易日上涨2.51%,最新总市值为36.92亿元。该股当日开盘29.51元,最高31.23元,最低28.58元,成交额达1.45亿元,换手率为8.43%。近日,金凯(辽宁)生命科技股份有限公司发布《2026年限制性股票与股票增值权激励计划(草案)》,拟向93名激励对象授予207.00万股限制性股票,占公司股本总额的1.72%,授予价格为15.13元/股;同时拟授予32.00万份股票增值权,占公司股本总额的0.27%,其中首次授予27.00万份,预留5.00万份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649026985","title":"金凯生科(301509)6月30日股东户数1.39万户,较上期增加5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649026985","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649026985?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:29","pubTimestamp":1783416565,"startTime":"0","endTime":"0","summary":"证券之星消息,近日金凯生科披露,截至2026年6月30日公司股东户数为1.39万户,较6月18日增加685.0户,增幅为5.19%。在医疗服务行业个股中,金凯生科股东户数低于行业平均水平,截至6月30日,医疗服务行业平均股东户数为4.85万户。从股价来看,2026年6月18日至2026年6月30日,金凯生科区间涨幅为11.64%,在此期间股东户数增加685.0户,增幅为5.19%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700029724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787343527390,"stockEarnings":[{"period":"1week","weight":-0.0882},{"period":"1month","weight":0.0948},{"period":"3month","weight":-0.0214},{"period":"6month","weight":-0.2028},{"period":"1year","weight":-0.2757},{"period":"ytd","weight":-0.0593}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":0.0099},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0433},{"period":"1year","weight":0.0356},{"period":"ytd","weight":-0.016}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"金凯(辽宁)生命科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15666人(较上一季度增加12.92%)","perCapita":"3621股","listingDate":"2023-08-03","address":"辽宁省阜新市阜新蒙古族自治县伊吗图镇氟化工园区安仁路6号","registeredCapital":"12044万元","survey":" 金凯(辽宁)生命科技股份有限公司的主营业务是提供小分子药物中间体以及少量原料药的定制研发生产服务。公司的主要产品是中间体。","listedPrice":56.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金凯生科(301509)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金凯生科(301509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金凯生科,301509,金凯生科股票,金凯生科股票老虎,金凯生科股票老虎国际,金凯生科行情,金凯生科股票行情,金凯生科股价,金凯生科股市,金凯生科股票价格,金凯生科股票交易,金凯生科股票购买,金凯生科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金凯生科(301509)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金凯生科(301509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}